Conference Correspondent

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

Third Interim Analysis from the Phase 2 Vision HO141 Trial of Venetoclax + Ibrutinib for Patients with R/R CLL: 15-Month Safety, Response, and MRD Evaluation
Read More
Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory Non-GCB DLBCL
Read More
Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with CLL/SLL: Updated Results from a Phase 1/2 Trial
Read More
Zanubrutinib in Patients with Treatment-Naïve CLL/SLL with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial
Read More
Four-Year Analysis of MURANO Study, Evaluating Fixed-Duration Venetoclax + Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia
Read More
Pooled Analysis of Ibrutinib versus Prior Regimen in Relapsed/Refractory Mantle-Cell Lymphoma with up to 7.5 Years of Extended Follow-Up
Read More
Alliance A041702 Phase 3 Study Comparing Ibrutinib + Obinutuzumab versus Ibrutinib + Venetoclax + Obinutuzumab in Untreated, Older Patients with CLL
Read More
Ixazomib, Rituximab, and Dexamethasone in Patients with Relapsed or Progressive Waldenström Macroglobulinemia
Read More
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab for First-Line Treatment of CLL with IGHV Mutation and without Del(17p)/Mutated TP53
Read More
Ibrutinib + Rituximab versus FCR in Younger Patients with CLL: Extended Follow-Up of E1912 Trial
Read More
Page 3 of 25
Results 21 - 30 of 242
SUBSCRIBE
Copyright © Amplity Medical Communications. All rights reserved.